other material
confidence high
sentiment positive
materiality 0.65
MacroGenics reports preliminary Phase 1 lorigerlimab data; 28.6% PSA50 in mCRPC
MACROGENICS INC
- 12 of 42 mCRPC patients (28.6%) achieved ≥50% PSA reduction; 9 of 42 (21.4%) achieved ≥90% PSA reduction.
- 9 of 35 evaluable patients (25.7%) had confirmed partial responses; median duration 4.6 months.
- TRAEs in 86.6% of patients; grade ≥3 TRAEs in 34.6%; 24.4% discontinued due to AEs; no fatal TRAEs.
- Company plans to initiate Phase 2 study in mCRPC in 2023.
- Median prior therapies: 2; 83% had prior docetaxel, 81% prior androgen receptor antagonist.